Family Medicine Board Review · Case-Based · Difficult Level

Anticoagulation — Complete Clinical Vignette MCQs

20 board-style cases built from the combined anticoagulation summary — LMWH/fondaparinux dosing, warfarin mechanism and INR management, DOAC selection and interactions, AFib risk scoring, bleeding management, and the full perioperative bridging framework. Tap "Reveal Answer" on each, then read the pearl.

20 Questions ●●●● Difficult Single Best Answer

Q1Fondaparinux — Renal Cutoff●●●●● Extreme

A 70-year-old man with acute VTE has a CrCl of 25 mL/min. His physician considers fondaparinux given its convenient once-daily dosing. Is this appropriate?

A. Yes, fondaparinux requires no renal adjustment
B. No — fondaparinux is contraindicated at CrCl <30 mL/min; an alternative agent should be used
C. Yes, but the dose should be doubled
D. No, fondaparinux is contraindicated in all patients regardless of renal function
E. Yes, since fondaparinux is eliminated hepatically, not renally

Reveal Answer

Correct answer: B

Fondaparinux is specifically contraindicated in patients with CrCl <30 mL/min — a stricter cutoff than the dose-reduction approach used for enoxaparin at the same threshold. His CrCl of 25 falls below this contraindication threshold.

Why the others are wrong A — fondaparinux does require renal consideration, with caution at CrCl 30-50 and contraindication below 30. C — dose adjustment isn't the solution; the drug is contraindicated outright at this renal function. D — it's not contraindicated in all patients, only at CrCl <30. E — fondaparinux is renally eliminated (18-hour half-life reflecting this), not hepatically.

Exam Pearl Fondaparinux: contraindicated at CrCl <30 — stricter than enoxaparin, which is dose-reduced (not contraindicated) at the same cutoff. Its 18-hour half-life is both an advantage (once-daily dosing) and a perioperative disadvantage (harder to reverse/clear).

Q2Warfarin Mechanism — VKOR●●●●● Extreme

A pharmacology question asks a resident to explain warfarin's precise molecular target. What is the correct mechanistic answer?

A. Warfarin directly binds and inhibits factor Xa
B. Warfarin inhibits vitamin K epoxide reductase (VKOR), blocking the cyclic regeneration of active vitamin K, which is required to activate factors II, VII, IX, X and proteins C and S
C. Warfarin directly inhibits thrombin
D. Warfarin has no effect on vitamin K metabolism
E. Warfarin acts primarily in the kidney, not the liver

Reveal Answer

Correct answer: B

Warfarin inhibits vitamin K epoxide reductase (VKOR), blocking the cyclic conversion of vitamin K back to its active/reduced form. Since active vitamin K is required as a cofactor to carboxylate (activate) factors II, VII, IX, X and the anticoagulant proteins C and S, this results in decreased activation of all of these factors — acting primarily in the liver.

Why the others are wrong A — direct factor Xa inhibition describes DOACs like apixaban/rivaroxaban, not warfarin. C — direct thrombin inhibition describes dabigatran, not warfarin. D — warfarin's entire mechanism centers on disrupting vitamin K metabolism/recycling. E — warfarin acts primarily in the liver, where these clotting factors are synthesized.

Exam Pearl Warfarin = VKOR inhibitor → blocks vitamin K recycling → ↓ activation of factors II, VII, IX, X AND proteins C/S. This single mechanistic fact explains both its therapeutic effect and its early paradoxical hypercoagulable window.

Q3Warfarin Dose Adjustment Rule●●●● Very Hard

A patient on warfarin 5mg daily (35mg/week total) has a subtherapeutic INR after excluding dietary and drug causes. Her physician wants to increase her dose by 10%. What is the most appropriate way to implement this adjustment?

A. Simply add an extra 5mg tablet on one random day of the week
B. Calculate the new total weekly dose (35mg × 1.10 = 38.5mg) and redistribute it across the week's daily doses, rather than changing a single day's dose in isolation
C. Double tomorrow's dose only, leaving the rest of the week unchanged
D. Dose adjustments should never be based on percentage changes
E. Skip a dose to compensate before increasing anything

Reveal Answer

Correct answer: B

Dose adjustments should target the total weekly dose, adjusted by 5-20%, not simply altering one day's tablet. Her current weekly total is 35mg; a 10% increase brings it to 38.5mg, which should be redistributed proportionally across her daily doses (not concentrated on a single day).

Why the others are wrong A — adding an extra tablet on one random day creates dosing inconsistency rather than a proper proportional weekly increase. C — doubling a single day's dose in isolation doesn't reflect the recommended total-weekly-dose adjustment strategy. D — the 5-20% weekly adjustment is specifically a percentage-based strategy. E — skipping a dose is the opposite of what's needed for a subtherapeutic (not supratherapeutic) INR.

Exam Pearl Adjust the TOTAL WEEKLY warfarin dose by 5-20%, not an individual day's dose. First always exclude dietary/drug/illness causes before making any dose change.

Q4INR Goal — Mechanical Mitral Valve●●●●● Extreme

A 55-year-old woman with a mechanical mitral valve replacement is on warfarin. Her most recent INR is 2.4. Is this within her appropriate target range?

A. Yes, 2.4 is within the standard 2-3 target used for most warfarin indications
B. No — mechanical mitral valve replacement specifically targets a HIGHER INR of 3.0 (range 2.5-3.5); her INR of 2.4 is below this target
C. Yes, mechanical mitral valves target a lower INR range than other indications
D. No, mechanical valves require an INR range of 4-5
E. INR targets don't apply to mechanical valve patients

Reveal Answer

Correct answer: B

Mechanical mitral valve replacement is the one indication with a specifically higher target INR: 3.0 (range 2.5-3.5) — reflecting the higher thrombotic risk in the mitral position compared with other valve positions or indications (which target the standard 2.5, range 2-3). Her INR of 2.4 falls below even the lower bound of her target range.

Why the others are wrong A — this applies the standard target, missing the mitral-valve-specific higher target. C — this reverses the relationship; mitral mechanical valves target higher, not lower, INR. D — 4-5 significantly overshoots the actual target range (2.5-3.5). E — INR targets specifically apply, and are specifically elevated, for this population.

Exam Pearl Memorize the one outlier: mechanical mitral valve = INR 3.0 (2.5-3.5). Every other listed indication (VTE, AFib, other valve replacements, antiphospholipid syndrome) targets the standard 2.5 (2-3).

Q5Supratherapeutic INR — Exact Vitamin K Dose●●●●● Extreme

A 74-year-old man on warfarin has an INR of 12 with no bleeding. His physician holds warfarin and wants to administer oral vitamin K. What is the appropriate dose?

A. 25-50 mg orally
B. 2.5-5 mg orally as one dose
C. No specific dose exists; any amount is acceptable
D. 100 mg IV push
E. 10-20 mg orally

Reveal Answer

Correct answer: B

For INR >10 without significant bleeding, the recommended oral vitamin K dose is 2.5-5 mg as a single dose, with the vitamin K antagonist held, monitoring frequency increased, and vitamin K repeated as necessary until INR is therapeutic.

Why the others are wrong A/E — these doses substantially exceed the recommended range for this clinical scenario. C — a specific, evidence-based dose range exists (2.5-5mg) and should be followed. D — IV administration at this high dose isn't the described approach for a non-bleeding patient; oral dosing at the lower 2.5-5mg range is appropriate here (IV vitamin K carries anaphylaxis risk and is generally reserved for more urgent/major bleeding scenarios).

Exam Pearl Exact number: oral vitamin K 2.5-5 mg for INR >10 without bleeding. Board questions often test whether you know this specific dose range rather than just "give vitamin K."

Q6Warfarin Perioperative — Bridging Decision●●●●● Extreme

A 67-year-old woman with hypertension and atrial fibrillation has been on warfarin for 10 years, hemodynamically stable with no AFib complications. Her CHA₂DS₂-VASc score is 3. She is scheduled for elective bladder sling surgery (a high bleeding risk procedure). What is the most appropriate perioperative management of her warfarin?

A. Continue warfarin without interruption
B. Discontinue warfarin the day prior to surgery and bridge with LMWH
C. Discontinue warfarin 2 days prior to surgery and restart it 2 days postoperatively unless there is a bleeding complication
D. Discontinue warfarin 5 days prior to surgery and restart it 12-24 hours postoperatively unless there is a bleeding complication
E. Discontinue warfarin 5 days prior to surgery and bridge with LMWH given her AFib diagnosis

Reveal Answer

Correct answer: D

This patient is at low risk for thromboembolism because her CHA₂DS₂-VASc score is 3 — bridging therapy in AFib is reserved for a CHA₂DS₂-VASc score ≥7 (or CHADS₂ 5-6). Since she is low-risk, no bridging is needed. Her surgery carries a high bleeding risk, so it's preferable to stop warfarin 5 days before the operation and restart it 12-24 hours postoperatively.

Why the others are wrong A — continuing warfarin uninterrupted through a high-bleeding-risk procedure is inappropriate. B — one day is insufficient given warfarin's ~5-day offset, and bridging isn't indicated for this low-risk patient. C — 2 days is an insufficient hold time for warfarin's pharmacokinetics. E — bridging is specifically NOT indicated here; her CHA₂DS₂-VASc of 3 places her well below the ≥7 threshold that would warrant bridging.

Exam Pearl Not every AFib patient on warfarin needs bridging — bridging is reserved for high thrombotic risk (CHA₂DS₂-VASc ≥7, CHADS₂ 5-6, recent stroke/TIA, mechanical mitral valve, recent VTE). A "garden-variety" AFib patient just needs the standard hold-and-restart (5 days before / 12-24h after for high-bleeding-risk surgery).

Q7DOAC — Edoxaban Renal Paradox●●●●● Extreme

A 45-year-old man with excellent renal function (CrCl 105 mL/min) and nonvalvular atrial fibrillation is being considered for edoxaban. Is this an appropriate choice?

A. Yes, excellent renal function is always favorable for any DOAC
B. No — edoxaban should specifically be avoided at CrCl >95 mL/min due to reduced efficacy observed at very high clearance in its pivotal trial
C. Yes, but only at double the standard dose
D. No, edoxaban is contraindicated in all patients regardless of renal function
E. Yes, since renal function only matters for reduced (not elevated) clearance

Reveal Answer

Correct answer: B

Edoxaban should specifically be avoided in patients with CrCl >95 mL/min — a counterintuitive renal cutoff, since very high renal clearance was associated with reduced efficacy in edoxaban's pivotal trial (increased drug elimination lowers effective drug exposure).

Why the others are wrong A — this is specifically NOT true for edoxaban; excellent renal function is a reason to avoid it, not favor it. C — doubling the dose isn't the described solution; an alternative agent should be chosen instead. D — edoxaban isn't universally contraindicated; it's specifically avoided at the high end of renal function. E — this statement is incorrect for edoxaban specifically, which has both a low-end (efficacy/safety) and high-end (efficacy) renal consideration.

Exam Pearl Edoxaban: avoid if CrCl >95 — the one DOAC renal cutoff that goes the "wrong way" (avoiding excellent renal function rather than impaired function). A classic counterintuitive board trap.

Q8DOAC Bleeding Profile Comparison●●●● Very Hard

A 70-year-old man with atrial fibrillation and a history of peptic ulcer disease needs anticoagulation. His physician wants to minimize GI bleeding risk while still using a DOAC. Which agent has the most favorable comparative bleeding profile for this concern?

A. Rivaroxaban, given its once-daily dosing convenience
B. Apixaban — associated with the lowest major bleeding risk among DOACs, while rivaroxaban and dabigatran carry higher GI bleeding risk
C. Dabigatran, given its rapid reversibility with idarucizumab
D. All DOACs carry identical GI bleeding risk
E. Edoxaban has the lowest bleeding risk of all DOACs

Reveal Answer

Correct answer: B

Apixaban is associated with the lowest major bleeding risk among the DOACs, while rivaroxaban and dabigatran specifically carry higher GI bleeding risk — making apixaban the more favorable choice for a patient with prior peptic ulcer disease and elevated GI bleeding concern.

Why the others are wrong A — dosing convenience doesn't address the bleeding risk concern, and rivaroxaban specifically carries higher GI bleeding risk. C — while reversibility is a reassuring feature, dabigatran itself carries higher GI bleeding risk, making it a less ideal choice for this specific concern. D — GI bleeding risk specifically differs among the DOACs; it is not identical. E — apixaban, not edoxaban, is specifically noted for the lowest major bleeding risk in this framework.

Exam Pearl Apixaban = lowest major bleeding risk; rivaroxaban and dabigatran = higher GI bleeding risk. This comparative bleeding profile is one of the most frequently tested DOAC-selection facts.

Q9Warfarin-Preferred Populations — Integrative●●●●● Extreme

Four patients on DOAC therapy are being reassessed by their physician: Patient A has developed severe liver impairment; Patient B has recurrent thrombosis despite adherence to her DOAC; Patient C has well-controlled hypertension only; Patient D has newly diagnosed antiphospholipid syndrome. In how many of these patients should switching to warfarin specifically be considered?

A. 1 patient
B. 2 patients
C. 3 patients — A, B, and D specifically fit recognized situations where warfarin may be preferable to DOACs; Patient C does not
D. All 4 patients
E. 0 patients, since DOACs are always preferred regardless of clinical scenario

Reveal Answer

Correct answer: C

Situations where warfarin may be preferable to DOACs include: severe renal impairment, severe liver impairment (Patient A), significant GI disease history, antiphospholipid syndrome (Patient D), recurrent thrombosis while on a DOAC (Patient B), and significant DOAC adverse effects. Patient C (well-controlled hypertension alone) does not fit any of these specific categories and can reasonably remain on a DOAC.

Why the others are wrong A/B — undercounts the number of patients meeting a warfarin-preferred criterion; three specific patients (A, B, D) meet named indications. D — Patient C's isolated hypertension alone doesn't meet any of the specific warfarin-preferred criteria. E — this ignores the specifically named exceptions where warfarin is preferred over DOACs.

Exam Pearl Warfarin-preferred situations: severe renal impairment, severe liver impairment, significant GI disease history, antiphospholipid syndrome, recurrent thrombosis on a DOAC, significant DOAC adverse effects — plus the earlier-established triad (mechanical valves, moderate-severe mitral stenosis). Memorize this expanded list.

Q10Anticoagulant Transitions●●●●● Extreme

A patient transitioning from warfarin to apixaban needs guidance on timing. A different patient transitioning from apixaban to warfarin also needs guidance. What are the correct transition strategies for each?

A. Both transitions require identical overlap strategies
B. Warfarin → apixaban: discontinue warfarin and start apixaban once INR falls below 2.0 (no overlap needed); apixaban → warfarin: start a parenteral anticoagulant and warfarin concurrently at the time of the next apixaban dose (overlap required)
C. Neither transition requires any specific timing considerations
D. Warfarin → apixaban requires overlap, while apixaban → warfarin requires no overlap
E. Both transitions should never be attempted; patients must remain on their original agent indefinitely

Reveal Answer

Correct answer: B

Transitioning warfarin → apixaban: discontinue warfarin, start apixaban once INR falls below 2.0 (no bridging overlap needed, since apixaban has rapid onset). Transitioning apixaban → warfarin: since warfarin has a delayed onset, start a parenteral anticoagulant AND warfarin concurrently at the time of the next scheduled apixaban dose, maintaining overlap until the INR is therapeutic.

Why the others are wrong A — the two transitions require fundamentally different strategies given warfarin's delayed vs. apixaban's rapid onset. C — both transitions require specific, defined timing protocols. D — this reverses the correct relationship; it's the transition TO warfarin that requires overlap, not FROM warfarin. E — both transitions are well-described, standard practice when clinically indicated.

Exam Pearl Going TO a DOAC from warfarin: wait for INR to drop below threshold (no overlap). Going TO warfarin from a DOAC: overlap with a parenteral bridge (warfarin's delayed onset requires it). The direction of the transition determines whether overlap is needed.

Q11ACCP Duration — First Unprovoked VTE●●●●● Extreme

A 45-year-old man has his first episode of unprovoked proximal DVT. His bleeding risk is assessed as low. What is the most appropriate duration of anticoagulation?

A. 3 months only, regardless of bleeding risk
B. Extended (lifelong) therapy is preferred over 3 months, given his low bleeding risk; bleeding risk should be reassessed annually
C. 1 month, then discontinue
D. No anticoagulation is indicated for a first unprovoked event
E. Exactly 6 months, with no further reassessment needed

Reveal Answer

Correct answer: B

For a first unprovoked proximal DVT/PE with low or moderate bleeding risk, extended (lifelong) therapy is preferred over 3 months. Bleeding risk should be reassessed annually to confirm extended therapy remains appropriate. (Contrast: if his bleeding risk were high, 3 months would be preferred over extended therapy instead.)

Why the others are wrong A — 3 months is the preferred duration only for high bleeding risk patients or provoked/reversible-risk-factor VTE, not for this low-bleeding-risk unprovoked case. C — 1 month is far shorter than any recommended duration. D — anticoagulation is clearly indicated for a first unprovoked VTE. E — a fixed 6-month course without reassessment doesn't reflect the recommended extended-therapy-with-annual-reassessment approach for this scenario.

Exam Pearl First unprovoked VTE: low/moderate bleeding risk → extended (lifelong) preferred over 3 months; high bleeding risk → 3 months preferred over extended. Reassess bleeding risk annually regardless of the initial decision.

Q12ACCP — Distal DVT Surveillance●●●●● Extreme

A 30-year-old woman has a first episode of distal DVT attributed to recent surgery. She has no severe symptoms and no risk factors for extension. What is the most appropriate initial management?

A. Immediate anticoagulation for 3 months, no alternative considered
B. Serial ultrasound surveillance for 2 weeks instead of anticoagulation; initiate anticoagulation only if extension occurs
C. No follow-up of any kind is needed
D. Immediate IVC filter placement
E. Extended lifelong anticoagulation regardless of clinical course

Reveal Answer

Correct answer: B

For a first distal DVT attributed to surgery or a reversible risk factor, without severe symptoms or risk factors for extension, the recommended approach is serial ultrasound surveillance for 2 weeks instead of anticoagulation — if surveillance shows extension, anticoagulation is then recommended (with treatment intensity/duration depending on whether it extends into proximal vessels).

Why the others are wrong A — immediate anticoagulation is reserved for patients with severe symptoms or risk factors for extension, not this favorable-profile case. C — surveillance (not complete inaction) is specifically recommended to catch extension. D — IVC filter placement is not indicated as first-line management for an uncomplicated distal DVT. E — extended lifelong therapy is not the recommended approach for this favorable, provoked, non-extending distal DVT scenario.

Exam Pearl Provoked distal DVT, no severe symptoms/extension risk factors: serial ultrasound surveillance × 2 weeks instead of anticoagulation. Risk factors for extension include: unexplained D-dimer elevation, extensive DVT (>5cm) or multi-vein involvement, proximity to proximal vein, unprovoked status, cancer, previous VTE, inpatient status.

Q13Cancer-Associated VTE — Guideline Evolution●●●●● Extreme

A hematology fellow notes that the ACCP table recommends LMWH over DOACs for cancer-associated VTE, while a more recent lecture states DOACs are now first-line even in cancer patients as of a 2025 update. How should this apparent discrepancy be resolved on a current exam?

A. The ACCP table is definitively correct and should always be followed regardless of publication date
B. Recognize that guidance has evolved — more recent 2025 guidance favors DOACs first-line even in cancer-associated VTE, superseding the older ACCP LMWH-preferred recommendation, though both exist in the literature
C. Neither recommendation is valid; no anticoagulant should be used in cancer-associated VTE
D. The two recommendations are identical and there is no discrepancy
E. LMWH and DOACs should always be given simultaneously in cancer patients

Reveal Answer

Correct answer: B

Guidance in this area has specifically evolved over time — the older ACCP table recommends LMWH over DOACs (grade 2C) for cancer-associated VTE, while a 2025 update shifts the recommendation to DOACs first-line even in cancer patients. On current exams, the more recent guidance should generally be followed, while recognizing that older literature/grading systems may still reference the LMWH-preferred approach.

Why the others are wrong A — treating an older recommendation as definitively correct ignores subsequent guideline evolution. C — anticoagulation remains clearly indicated in cancer-associated VTE; this option is factually wrong. D — the two recommendations are specifically different (LMWH-preferred vs. DOAC-preferred), not identical. E — simultaneous dual anticoagulation isn't the described approach; it's a choice between agents, not combination therapy.

Exam Pearl Medical guidance changes over time — recognize that cancer-associated VTE anticoagulant preference has shifted from LMWH to DOAC-first as of 2025. When conflicting information appears across sources, prioritize the most current guidance while understanding the older standard for context.